

Exhibit 1
MINDRAY MEDICAL INTERNATIONAL LIMITED
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands of US dollars)

	As of December 31, 2014	As of September 30, 2015
	US\$	US\$
	(Note 1)	(unaudited)
ASSETS		
Current assets:		
Cash and cash equivalents (Note 2)	276,598	197,708
Restricted cash (Note 3)	7,422	28
Restricted investments (Note 4)	-	234,622
Short-term investments (Note 2)	816,394	525,688
Accounts receivable, net	222,522	175,959
Inventories	150,642	180,030
Value added tax receivables	3,432	8,790
Other receivables and current assets	23,316	155,564
Prepayments and deposits	16,481	25,471
Deferred tax assets, net	14,802	18,482
Total current assets	1,531,609	1,522,342
Restricted cash, non-current (Note 3)	5,061	2,769
Restricted investment, non-current (Note 5)	-	7,074
Other assets	9,666	8,835
Accounts receivables, net, non-current	3,350	2,623
Advances for purchase of plant and equipment	21,840	19,579
Property, plant and equipment, net	412,733	440,150
Land use rights, net	59,057	55,805
Intangible assets, net	175,451	156,978
Goodwill	254,435	251,205
Total assets	2,473,202	2,467,360
LIABILITIES AND EQUITY		
Current liabilities:		
Short-term bank loans	59,625	249,629
Notes payable	9,234	5,829
Accounts payable	93,523	100,284
Advances from customers	31,396	48,361
Salaries payable	114,583	97,275
Other payables and current liabilities	168,139	163,383
Purchase consideration payable	17,173	7,090
Income taxes payable	20,415	32,713
Other taxes payable	10,342	6,199
Total current liabilities	524,430	710,763
Long-term bank loans	197,585	48,000
Other long-term liabilities	10,670	11,155
Deferred tax liabilities, net	69,233	78,815
Total liabilities	801,918	848,733
Mindray shareholders' equity:		
Ordinary shares	15	15
Additional paid-in capital	453,564	433,872
Retained earnings	1,000,257	1,077,366
Accumulated other comprehensive income	144,120	68,292
Total Mindray shareholders' equity	1,597,956	1,579,545
Non-controlling interests	73,328	39,082
Total equity	1,671,284	1,618,627
Total liabilities and equity	2,473,202	2,467,360

- (1) Financial information is extracted from the audited financial statements included in the Company's 2014 annual report on Form 20-F.
- (2) In respect of cash and cash equivalents and short-term investments, there is an aggregate compensating balance arrangement of \$189,000 and \$nil as of December 31, 2014 and September 30, 2015, respectively in relation to the drawings of certain bank loans.
- (3) Restricted cash as of December 31, 2014 is mainly those purchase consideration in connection with our acquisitions being held on escrow accounts.
- (4) Restricted investments are those investments in Chinese Renminbi denominated financial products placed with bank which are restricted as to withdrawal or usage according to new terms imposed on certain bank loans during the quarter ended March 31, 2015.

- (5) Restricted investment, non-current is the purchase consideration being held as time deposit which is restricted as withdrawal or usage for over one year in connection with our acquisition.

Exhibit 2
MINDRAY MEDICAL INTERNATIONAL LIMITED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands of US dollars, except share and per share amounts)

	Three months ended September 30,		Nine months ended September 30,	
	2014	2015	2014	2015
	US\$ (unaudited)	US\$ (unaudited)	US\$ (unaudited)	US\$ (unaudited)
Net revenues				
- <i>China</i>	155,699	152,567	423,996	428,388
- <i>International</i>	168,937	175,048	499,863	508,508
Net revenues	324,636	327,615	923,859	936,896
Cost of revenues	(141,799)	(148,818)	(405,787)	(425,031)
Gross profit	182,837	178,797	518,072	511,865
Selling expenses	(65,800)	(62,541)	(184,067)	(182,859)
General and administrative expenses	(39,293)	(20,439)	(96,684)	(81,385)
Research and development expenses	(34,346)	(37,093)	(98,213)	(107,982)
Income from operations	43,398	58,724	139,108	139,639
Other income, net	631	1,796	2,225	3,589
Interest income	9,530	7,589	27,987	21,919
Interest expense	(1,462)	(1,082)	(5,148)	(3,175)
Income before income taxes and non-controlling interests	52,097	67,027	164,172	161,972
Income tax provision	(4,729)	(14,825)	(18,677)	(33,288)
Net income	47,368	52,202	145,495	128,684
Less: Net income attributable to non-controlling interests	(1,325)	(1,331)	(4,196)	(4,478)
Net income attributable to Mindray shareholders	46,043	50,871	141,299	124,206
Basic earnings per share	0.39	0.43	1.21	1.05
Diluted earnings per share	0.39	0.43	1.19	1.05
Shares used in the computation of:				
Basic earnings per share	117,106,169	117,846,734	116,979,193	117,830,960
Diluted earnings per share	118,231,031	118,657,681	118,315,564	118,818,946

Exhibit 3
MINDRAY MEDICAL INTERNATIONAL LIMITED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands of US dollars)

	Three months ended September 30,		Nine months ended September 30,	
	2014	2015	2014	2015
	US\$	US\$	US\$	US\$
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
Cash flow from operating activities:				
Net income	47,368	52,202	145,495	128,684
Adjustments to reconcile net income to net cash provided by operating activities	22,969	27,437	71,666	82,819
Changes in assets and liabilities, net of effects of acquisitions	15,187	29,208	(27,372)	(3,579)
Net cash provided by operating activities	85,524	108,847	189,789	207,924
Cash flow from investing activities:				
Acquisition cost of subsidiaries, net of cash received	(852)	(11,113)	(9,067)	(16,691)
Capital expenditures	(28,057)	(27,239)	(79,108)	(78,335)
Decrease (increase) in restricted cash	724	10,699	(790)	9,730
Increase in restricted investments	-	(7,354)	-	(59,499)
Proceeds from sale of short-term investments	184,247	424,208	800,762	576,779
Increase in short-term investments and changes in other investing activities	(407,911)	(514,776)	(749,649)	(646,957)
Net cash used in investing activities	(251,849)	(125,575)	(37,852)	(214,973)
Cash flow from financing activities:				
Repayment of bank loans	-	-	(210,000)	(4,375)
Proceeds from bank loans, net of costs	-	-	-	47,712
Dividend paid	-	-	(58,711)	(47,097)
Proceeds from exercise of options	1,731	81	2,745	1,938
Repurchase of ordinary American depositary shares	-	-	(68,080)	-
Cash paid to acquire a non-controlling interest	-	(64,074)	(4,731)	(64,074)
Cash contribution from a non-controlling interest	416	-	655	-
Net cash provided by (used in) financing activities	2,147	(63,993)	(338,122)	(65,896)
Net decrease in cash and cash equivalents	(164,178)	(80,721)	(186,185)	(72,945)
Cash and cash equivalents, beginning of period	362,311	284,194	385,224	276,598
Effect of exchange rate changes on cash and cash equivalents	(749)	(5,765)	(1,655)	(5,945)
Cash and cash equivalents, end of period	197,384	197,708	197,384	197,708

Exhibit 4
MINDRAY MEDICAL INTERNATIONAL LIMITED
RECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE NEAREST COMPARABLE GAAP MEASURES

(In thousands of US dollars, except share and per share amounts)

	Three months ended September 30,		Nine months ended September 30,	
	2014	2015	2014	2015
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
	US\$	US\$	US\$	US\$
Non-GAAP net income attributable to the Company	56,157	60,386	168,430	149,340
<i>Non-GAAP net margin</i>	17.3%	18.4%	18.2%	15.9%
Amortization of acquired intangible assets	(3,499)	(3,243)	(10,384)	(9,935)
Deferred tax impact related to acquired intangible assets	662	613	1,881	1,848
Dispute related legal fees, net of tax impact	(2,340)	(2,446)	(2,340)	(5,266)
Going private related expenses, net of tax impact	-	(874)	-	(874)
Share-based compensation	(4,937)	(3,565)	(16,288)	(10,907)
GAAP net income attributable to the Company	46,043	50,871	141,299	124,206
<i>GAAP net margin</i>	14.2%	15.5%	15.3%	13.3%
Non-GAAP basic earnings per share	0.48	0.51	1.44	1.27
Non-GAAP diluted earnings per share	0.47	0.51	1.42	1.26
GAAP basic earnings per share	0.39	0.43	1.21	1.05
GAAP diluted earnings per share	0.39	0.43	1.19	1.05
Shares used in computation of:				
Basic earnings per share	117,106,169	117,846,734	116,979,193	117,830,960
Diluted earnings per share	118,231,031	118,657,681	118,315,564	118,818,946
Non-GAAP operating income	54,434	69,284	168,380	167,550
<i>Non-GAAP operating margin</i>	16.8%	21.1%	18.2%	17.9%
Amortization of acquired intangible assets	(3,499)	(3,243)	(10,384)	(9,935)
Dispute related legal fees	(2,600)	(2,878)	(2,600)	(6,195)
Going private related expenses	-	(874)	-	(874)
Share-based compensation	(4,937)	(3,565)	(16,288)	(10,907)
GAAP operating income	43,398	58,724	139,108	139,639
<i>GAAP operating margin</i>	13.4%	17.9%	15.1%	14.9%
Non-GAAP gross profit	185,119	180,664	524,657	517,633
<i>Non-GAAP gross margin</i>	57.0%	55.1%	56.8%	55.2%
Amortization of acquired intangible assets	(1,808)	(1,672)	(5,676)	(5,186)
Share-based compensation	(474)	(195)	(909)	(582)
GAAP gross profit	182,837	178,797	518,072	511,865
<i>GAAP gross margin</i>	56.3%	54.6%	56.1%	54.6%
Non-GAAP selling expenses	(61,486)	(59,708)	(174,245)	(174,175)
<i>Non-GAAP as % of total net revenues</i>	18.9%	18.2%	18.9%	18.6%
Amortization of acquired intangible assets	(1,691)	(1,571)	(4,708)	(4,749)
Share-based compensation	(2,623)	(1,262)	(5,114)	(3,935)
GAAP selling expenses	(65,800)	(62,541)	(184,067)	(182,859)
<i>GAAP as % of total net revenues</i>	20.3%	19.1%	19.9%	19.5%
Non-GAAP general and administrative expenses	(36,061)	(15,770)	(87,467)	(71,628)
<i>Non-GAAP as % of total net revenues</i>	11.1%	4.8%	9.5%	7.6%
Dispute related legal fees	(2,600)	(2,878)	(2,600)	(6,195)
Going private related expenses	-	(874)	-	(874)
Share-based compensation	(632)	(917)	(6,617)	(2,688)
GAAP general and administrative expenses	(39,293)	(20,439)	(96,684)	(81,385)
<i>GAAP as % of total net revenues</i>	12.1%	6.2%	10.5%	8.7%
Non-GAAP research and development expenses	(33,138)	(35,902)	(94,565)	(104,280)
<i>Non-GAAP as % of total net revenues</i>	10.2%	11.0%	10.2%	11.1%
Share-based compensation	(1,208)	(1,191)	(3,648)	(3,702)
GAAP research and development expenses	(34,346)	(37,093)	(98,213)	(107,982)
<i>GAAP as % of total net revenues</i>	10.6%	11.3%	10.6%	11.5%

Exhibit 5**MINDRAY MEDICAL INTERNATIONAL LIMITED****RECONCILIATION OF GAAP NET INCOME TO EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION AND AMORTIZATION****(In thousands of US dollars)**

	Three months ended September 30,		Nine months ended September 30,	
	2014	2015	2014	2015
	US\$ (unaudited)	US\$ (unaudited)	US\$ (unaudited)	US\$ (unaudited)
GAAP net income attributable to the Company	46,043	50,871	141,299	124,206
Interest income	(9,530)	(7,589)	(27,987)	(21,919)
Interest expense	1,462	1,082	5,148	3,175
Income tax provision	4,729	14,825	18,677	33,288
Earnings before interest and taxes ("EBIT")	42,704	59,189	137,137	138,750
Depreciation	9,070	9,651	26,402	29,422
Amortization	5,743	5,304	16,889	16,274
Earnings before interest, taxes, depreciation, and amortization ("EBITDA")	<u>57,517</u>	<u>74,144</u>	<u>180,428</u>	<u>184,446</u>